Analysts expect Aimmune Therapeutics Inc (NASDAQ:AIMT) to post ($0.91) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aimmune Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($1.07). Aimmune Therapeutics posted earnings of ($0.81) per share during the same quarter last year, which suggests a negative year over year growth rate of 12.3%. The business is scheduled to issue its next quarterly earnings results on Monday, March 11th.
On average, analysts expect that Aimmune Therapeutics will report full year earnings of ($3.55) per share for the current year, with EPS estimates ranging from ($3.79) to ($3.30). For the next fiscal year, analysts expect that the business will post earnings of ($3.52) per share, with EPS estimates ranging from ($4.30) to ($2.57). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.03.
Several research analysts recently weighed in on AIMT shares. ValuEngine cut Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 7th. Stifel Nicolaus set a $33.00 price target on Aimmune Therapeutics and gave the company a “hold” rating in a research report on Sunday, November 11th. Cantor Fitzgerald set a $62.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, October 15th. BidaskClub cut Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 11th. Finally, Roth Capital set a $80.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Aimmune Therapeutics presently has an average rating of “Buy” and an average target price of $51.70.
AIMT stock traded up $0.11 during trading on Tuesday, hitting $23.86. 32,376 shares of the company traded hands, compared to its average volume of 789,511. The stock has a market cap of $1.31 billion, a P/E ratio of -9.14 and a beta of -0.13. Aimmune Therapeutics has a 1 year low of $21.47 and a 1 year high of $42.00.
In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas acquired 3,650 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was acquired at an average cost of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the transaction, the insider now directly owns 63,600 shares of the company’s stock, valued at $1,752,816. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 24.56% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Tiverton Asset Management LLC purchased a new stake in shares of Aimmune Therapeutics during the second quarter worth approximately $145,000. Ardsley Advisory Partners purchased a new stake in shares of Aimmune Therapeutics during the second quarter worth approximately $202,000. Atria Investments LLC purchased a new stake in shares of Aimmune Therapeutics during the third quarter worth approximately $213,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Aimmune Therapeutics during the third quarter worth approximately $221,000. Finally, Rehmann Capital Advisory Group increased its position in shares of Aimmune Therapeutics by 2,242.4% during the third quarter. Rehmann Capital Advisory Group now owns 6,465 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 6,189 shares in the last quarter. Hedge funds and other institutional investors own 75.04% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Recommended Story: Book Value Per Share in Stock Trading
Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.